Find and Pitch Jounalists, Get Your Story Covered

Tags: Isomorphic Labs Eli Lilly

	Profile	Recent Articles on Subject
1	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected - about 2 months ago Eli Lilly’s Zepbound Leads to Greater Weight Loss vs. Novo Nordisk Drug in Head-to-Head Test - 3 months ago Eli Lilly Plans $4.5B Medicine Foundry to Foster Innovations in Drug Manufacturing - 5 months ago Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative - 6 months ago With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs - 6 months ago Eli Lilly Drug Reduces Risk of Diabetes Onset, Building Case for Broader Use of the Therapy - 7 months ago Eli Lilly Shows Appetite for Oral Immunology Drugs, Swallowing Morphic in $3.2B Deal - 8 months ago Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi - 8 months ago Eli Lilly Puts $1B on the Line to Expand its Cancer Radiopharmaceuticals Prospects - 8 months ago Eli Lilly Pumps $5.3B More Into Site for Making Metabolic Meds Zepbound & Mounjaro - 9 months ago
2	Parkev Tatevosian, CFA Motley Fool Finance, Economics Professor. Writes for The Motley Fool. YouTube Content Creator. FinanceEconomicsEducation	Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk - about 2 months ago
3	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Eli Lilly seeks to join lawsuit on compounded drugs - about 2 months ago Eli Lilly releases new data on weekly insulin - 6 months ago Lilly has more positive data on its weekly insulin - 6 months ago Eli Lilly’s anti-vanity ad campaign for Oscars - 12 months ago
4	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious - 3 months ago Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock? - about 1 year ago Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning - over 1 year ago Where Will Eli Lilly Be in 5 Years? - over 1 year ago Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next? - over 1 year ago
5	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves - 3 months ago
6	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model - 3 months ago Eli Lilly follows J&J in suing Biden administration over 340B rebates - 4 months ago
7	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago
8	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 7 months ago As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them - 8 months ago STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 8 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - over 1 year ago
9	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight - 4 months ago STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more - 12 months ago STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more - 12 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - over 1 year ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - over 1 year ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage - 4 months ago Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies - 6 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 10 months ago

Journalists covering Eli Lilly